Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses
Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses
复制标题
DOI：
10.1016/j.vaccine.2005.03.037
复制
发表时间：
2005-07-14
期刊：
影响因子：
5.5
通讯作者：
Fooks, AR
中科院分区：
文献类型：
--
作者：
Brookes, SM;Parsons, G;Fooks, AR
使用改良荧光抗体病毒中和（mFAVN）试验评价了针对狂犬病人二倍体细胞疫苗（HDCV）诱导的抗体中和欧洲蝙蝠狂犬病毒（EBLV 1型和2型）、澳大利亚蝙蝠狂犬病毒和经典狂犬病病毒（RABV）的能力。96%（48/50）的人接种后血清检测交叉中和这些病毒（>= 0.5 IU/ml）。还评估了使用近交系小鼠（RIII，k/k单倍型）的交叉保护实验。给予小鼠HDCV（两次腹膜内途径），并用致死剂量（25 MLD 50）的单个病毒进行攻击（颅内或外周）。该疫苗在80-100%经外周途径攻毒的动物中提供了统计学显著保护。保护水平在颅内（i.c.）挑战.我们的数据为使用狂犬病HDCV对狂犬病I组狂犬病毒的广谱交叉中和和交叉保护提供了强有力的证据。皇冠版权所有（c）2005年出版的爱思唯尔有限公司保留所有权利。
The ability of antibodies elicited against the rabies human diploid cell vaccine (HDCV) to neutralise European bat Lyssaviruses (EBLV types-1 and -2), Australian bat Lyssavirus and classical rabies virus (RABV) has been evaluated using modified fluorescent antibody virus neutralisation (mFAVN) assays. Ninety-six percent (48 of 50) of the human post-vaccinated sera tested cross-neutralised these viruses (>= 0.5 IU/ml). Cross-protection experiments using inbred mice (RIII, k/k haplotype) were also assessed. Mice were given HDCV (twice by the intra-peritoneal route) and challenged (intra-cranially or peripherally) with a lethal dose (25 MLD50) of the individual viruses. The vaccine conferred statistically significant protection in 80-100% of animals challenged via the peripheral route. Levels of protection were lower following intra-cranial (i.c.) challenge. Our data provides strong evidence for broad spectrum cross-neutralisation and cross-protection of phylogroup I lyssaviruses using rabies HDCV. Crown Copyright (c) 2005 Published by Elsevier Ltd. All rights reserved.